HIGHLIGHTS
- who: A. Selvarajah from the disease (CAD) in the Netherlands have published the research: Feasibility and safety of cangrelor in patients with suboptimal P2Y, in the Journal: (JOURNAL)
- what: The authors propose a registry in the Netherlands, studying the feasibility and safety of cangrelor in high thrombotic risk patients with suboptimal P2Y12 inhibition who undergo (primary) PCI.
SUMMARY
(CAD) undergoing (primary) percutaneous coronary intervention (PCI) to prevent adverse ischemic complications. Clopidogrel as well as the stronger P 2Y12 inhibitors ticagrelor and prasugrel are the recommended and most commonly used oral P2Y12 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.